NCT03001622已完成2 期
An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- InflaRx GmbH
- 入组人数
- 12
- 试验地点
- 2
- 主要终点
- Number of patients with at least possibly related treatment-emergent adverse events (TEAEs)
研究概览
简要总结
The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints (e.g., Hidradenitis Suppurativa Clinical Response (HiSCR), Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) for disease, VAS for pain, Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA), Modified Sartorius Score (mSS)).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ≥ 18 years old
- •Written informed consent
- •Diagnosis of HS for at least 1 year
- •Hidradenitis suppurativa (HS) lesions in at least 2 distinct anatomic areas, one of which is Hurley Stage II or III
- •Total AN (abscesses and nodules) count ≥3
- •Patients with either primary or secondary failure of biological treatment or are not eligible for treatment with other biologicals
- •Failure of previous antimicrobial treatments
排除标准
- •Body weight above 150 kg or body weight below 60 kg
- •Has a draining fistula count of greater than 30 at baseline
- •Surgical management planned within the next 24 weeks
- •Occurrence of a flare-up of HS leading to intravenous antimicrobial treatment within the last 14 days
- •Any other disease and condition that is likely to interfere with evaluation of study product, outcome assessment or satisfactory conduct of the study
- •Active infection
- •Severe congestive heart failure (i.e., New York Heart Association (NYHA) Class IV)
- •History of systemic lupus erythematosus or rheumatoid arthritis
- •Any immunodeficiency disease
- •Active hematological or solid malignant tumor
- •Patients must not have had any other active skin disease or condition (e.g., bacterial, fungal, or viral infection) that may have interfered with assessment of HS.
- •One of the following abnormal laboratory results
- •White blood cell count < 2,500/mm3
- •Neutrophil count < 1000/mm3
- •Serum Creatinine > 3 x Upper Normal Limit (UNL)
- •Total Bilirubin > 2 x UNL
- •Alanine-Aminotransferase (ALAT) > 2 x UNL
- •Positive screening test for Hepatitis B, Hepatitis C, or HIV 1/2
- •Prior administration of any biological compound in the last 3 months
- •Intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1 mg/kg for the last three weeks;
- •Intake of Immunosuppressive drugs within past 30 days (e.g., cyclosporine, tacrolimus)
- •General exclusion criteria
- •Pregnant (in women of childbearing potential an urine pregnancy test has to be performed) or breast-feeding women
- •Women with childbearing potential (defined as within two years of their last menstruation) not willing to practice appropriate contraceptive measures (e.g., implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy, abstinence) while participating in the trial
- •Participation in any interventional clinical trial within the last three months
- •Known intravenous drug abuse
- •Employee at the study site, spouse/partner or relative of any study staff (e.g., investigator, sub-investigators, or study nurse) or relationship to the sponsor
结局指标
主要结局
Number of patients with at least possibly related treatment-emergent adverse events (TEAEs)
时间窗: up to Day 134
Number of patients with detection of anti-drug antibodies (pre-/post-dosing)
时间窗: up to Day 134
次要结局
- Plasma concentration of C5a(Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134)
- Percentage change from baseline in total abscess and nodule (AN) count per time point(Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134)
- Hidradenitis Suppurativa Clinical Response (HiSCR) per time point(Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134)
- Achievement of Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA) of clear, minimal, or mild among patients with at least 2 grades improvement (reduction) from baseline(Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134)
- HS-PGA score per time point(Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134)
- VAS disease score per time(At each visit from Day 1 until Day 134)
- Plasma concentration of IFX-1(From Day 1 until Day 134)
- Change from baseline in VAS disease score per time point(At each visit from Day 1 until Day 134)
- Achievement of at least a 30% reduction and at least a 10 mm reduction in the Visual Analog Scale (VAS) for pain, among patients who had a baseline pain assessment ≥ 30 mm(At each visit from Day 1 until Day 134)
- VAS pain score per time point(At each visit from Day 1 until Day 134)
- Change from baseline in VAS pain score per time point(At each visit from Day 1 until Day 134)
- Change from baseline in DLQI per time point(Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134)
- Dermatology Life Quality Index (DLQI) per time point(Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis SuppurativaHidradenitis SuppurativaNCT05849922Sanofi86
已完成
2 期
Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis SuppurativaHidradenitis SuppurativaNCT05819398Boehringer Ingelheim209
Unknown
1 期
P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular CarcinomaHepatocellular CarcinomaNCT04233840National Taiwan University Hospital72
尚未招募
2 期
Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRCCRCNCT05239650Shanghai Henlius Biotech50
招募中
1 期
A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.Breast CancerNCT05845138Suzhou Suncadia Biopharmaceuticals Co., Ltd.116